Reich Kristian's Form 4 filing
MoonLake Immunotherapeutics (MLTX) · filed Feb 22, 2024
- Accession no.
- 0001213900-24-016240
- Filed
- Feb 22, 2024
- Trade date
- Feb 20-21, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.21M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Reich KristianCIK 0001920553 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 20, 2024 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −10,000 | $57.45 | −$574,500 | 2,987,483 | Indirect | |
| Feb 20, 2024 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −10,000 | $57.43 | −$574,300 | 100,071 | Direct | |
| Feb 21, 2024 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −509 | $55.31 | −$28,152.79 | 2,986,974 | Indirect | |
| Feb 21, 2024 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −569 | $55.30 | −$31,465.7 | 99,502 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.